JCI Insight (Mar 2021)

PDLIM2 repression by ROS in alveolar macrophages promotes lung tumorigenesis

  • Liwen Li,
  • Fan Sun,
  • Lei Han,
  • Xujie Liu,
  • Yadong Xiao,
  • Alyssa D. Gregory,
  • Steven D. Shapiro,
  • Gutian Xiao,
  • Zhaoxia Qu

Journal volume & issue
Vol. 6, no. 5

Abstract

Read online

One of the most fundamental and challenging questions in the field of cancer is how immunity is transformed from tumor immunosurveillance to tumor-promoting inflammation. Here, we identified the tumor suppressor PDZ-LIM domain–containing protein 2 (PDLIM2) as a checkpoint of alveolar macrophages (AMs) important for lung tumor suppression. During lung tumorigenesis, PDLIM2 expression in AMs is downregulated by ROS-activated transcription repressor BTB and CNC homology 1 (BACH1). PDLIM2 downregulation leads to constitutive activation of the transcription factor STAT3, driving AM protumorigenic polarization/activation and differentiation from monocytes attracted from the circulation to suppress cytotoxic T lymphocytes and promote lung cancer. PDLIM2 downregulation also decreases AM phagocytosis. These findings establish ROS/BACH1/PDLIM2/STAT3 as a signaling pathway driving AMs for lung tumor promotion.

Keywords